{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:04:15Z","timestamp":1791313455105,"version":"4.3.1"},"reference-count":105,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:00:00Z","timestamp":1621382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:00:00Z","timestamp":1621382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s40620-021-01062-6","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T05:02:49Z","timestamp":1621400569000},"page":"397-415","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Therapeutic advances in ADPKD: the future awaits"],"prefix":"10.1093","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6559-196X","authenticated-orcid":false,"given":"Ivana","family":"Capuano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Buonanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Riccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Amicone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pisani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,5,19]]},"reference":[{"issue":"10","key":"1062_CR1","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1681\/ASN.2018050493","volume":"29","author":"MB Lanktree","year":"2018","unstructured":"Lanktree MB, Haghighi A, Guiard E et al (2018) Prevalence estimates of polycystic kidney and liver disease by population sequencing. J Am Soc Nephrol 29(10):2593\u20132600","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"1062_CR2","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1172\/JCI72272","volume":"124","author":"PC Harris","year":"2014","unstructured":"Harris PC, Torres VE (2014) Genetic mechanisms and signalling pathways in autosomal dominant polycystic kidney disease. J Clin Invest 124(6):2315\u20132324","journal-title":"J Clin Invest"},{"issue":"1 Pt 1","key":"1062_CR3","doi-asserted-by":"publisher","first-page":"C389","DOI":"10.1152\/ajpcell.1996.270.1.C389","volume":"270","author":"K Hanaoka","year":"1996","unstructured":"Hanaoka K, Devuyst O, Schwiebert EM et al (1996) A role for CFTR in human autosomal dominant polycystic kidney disease. Am J Physiol 270(1 Pt 1):C389\u2013C399","journal-title":"Am J Physiol"},{"issue":"9","key":"1062_CR4","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1128\/MCB.01259-08","volume":"29","author":"G Distefano","year":"2009","unstructured":"Distefano G, Boca M, Rowe I et al (2009) Polycystin-1 regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1. Mol Cell Biol 29(9):2359\u20132371","journal-title":"Mol Cell Biol"},{"issue":"5","key":"1062_CR5","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1002\/hep.23511","volume":"51","author":"C Spirli","year":"2010","unstructured":"Spirli C, Okolicsanyi S, Fiorotto R et al (2010) Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice. Hepatology 51(5):1778\u20131788","journal-title":"Hepatology"},{"issue":"1","key":"1062_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ydbio.2012.01.014","volume":"364","author":"TF Gallegos","year":"2012","unstructured":"Gallegos TF, Kouznetsova V, Kudlicka K et al (2012) A protein kinase A and Wnt-dependent network regulating an intermediate stage in epithelial tubulogenesis during kidney development. Dev Biol 364(1):11\u201321","journal-title":"Dev Biol"},{"issue":"2","key":"1062_CR7","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.cub.2009.11.072","volume":"20","author":"TY Besschetnova","year":"2010","unstructured":"Besschetnova TY, Kolpakova-Hart E, Guan Y et al (2010) Identification of signalling pathways regulating primary cilium length and flow-mediated adaptation. Curr Biol 20(2):182\u2013187","journal-title":"Curr Biol"},{"issue":"2","key":"1062_CR8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ccr.2010.06.018","volume":"18","author":"AA Ahmed","year":"2010","unstructured":"Ahmed AA, Lu Z, Jennings NB et al (2010) SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. Cancer Cell 18(2):109\u2013121","journal-title":"Cancer Cell"},{"issue":"5","key":"1062_CR9","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1681\/ASN.2006111215","volume":"18","author":"BK Yoder","year":"2007","unstructured":"Yoder BK (2007) Role of primary cilia in the pathogenesis of polycystic kidney disease. J Am Soc Nephrol 18(5):1381\u20131388","journal-title":"J Am Soc Nephrol"},{"key":"1062_CR10","doi-asserted-by":"publisher","first-page":"4367019","DOI":"10.1155\/2017\/4367019","volume":"2017","author":"Y \u00c1valos","year":"2017","unstructured":"\u00c1valos Y, Pe\u00f1a-Oyarzun D, Budini M et al (2017) New roles of the primary cilium in autophagy. Biomed Res Int 2017:4367019","journal-title":"Biomed Res Int"},{"key":"1062_CR11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1146\/annurev.physiol.70.113006.100621","volume":"71","author":"J Zhou","year":"2009","unstructured":"Zhou J (2009) Polycystins and primary cilia: primers for cell cycle progression. Annu Rev Physiol 71:83\u2013113","journal-title":"Annu Rev Physiol"},{"issue":"10","key":"1062_CR12","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/nm935","volume":"9","author":"VH Gattone","year":"2003","unstructured":"Gattone VH, Wang X, Harris PC et al (2003) Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 9(10):1323\u20131326","journal-title":"Nat Med"},{"issue":"12","key":"1062_CR13","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/ki.2008.111","volume":"73","author":"PG Starremans","year":"2008","unstructured":"Starremans PG, Li X, Finnerty PE et al (2008) A mouse model for polycystic kidney disease through a somatic in-frame deletion in the 5\u2019 end of Pkd1. Kidney Int 73(12):1394\u20131405","journal-title":"Kidney Int"},{"issue":"9","key":"1062_CR14","doi-asserted-by":"publisher","first-page":"F931","DOI":"10.1152\/ajprenal.00604.2013","volume":"306","author":"KV Juul","year":"2014","unstructured":"Juul KV, Bichet DG, Nielsen S et al (2014) The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors. Am J Physiol Renal Physiol 306(9):F931\u2013F940","journal-title":"Am J Physiol Renal Physiol"},{"issue":"25","key":"1062_CR15","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O et al (2012) Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367(25):2407\u20132418","journal-title":"N Engl J Med"},{"issue":"6","key":"1062_CR16","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.ekir.2017.07.004","volume":"2","author":"O Devuyst","year":"2017","unstructured":"Devuyst O, Chapman AB, Shoaf SE et al (2017) Tolerability of aquaretic-related symptoms following tolvaptan for autosomal dominant polycystic kidney disease: results from TEMPO 3:4. Kidney Int Rep 2(6):1132\u20131140","journal-title":"Kidney Int Rep"},{"issue":"3","key":"1062_CR17","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/ndt\/gfx043","volume":"33","author":"VE Torres","year":"2018","unstructured":"Torres VE, Chapman AB, Devuyst O et al (2018) Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrol Dial Transplant 33(3):477\u2013489","journal-title":"Nephrol Dial Transplant"},{"issue":"20","key":"1062_CR18","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","volume":"377","author":"VE Torres","year":"2017","unstructured":"Torres VE, Chapman AB, Devuyst O (2017) Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med 377(20):1930\u20131942","journal-title":"N Engl J Med"},{"issue":"3","key":"1062_CR19","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ekir.2017.01.003","volume":"2","author":"RD Perrone","year":"2017","unstructured":"Perrone RD, Mouksassi MS, Romero K et al (2017) Total kidney volume is a prognostic biomarker of renal function decline and progression to end-stage renal disease in patients with autosomal dominant polycystic kidney disease. Kidney Int Rep 2(3):442\u201345020","journal-title":"Kidney Int Rep"},{"issue":"10","key":"1062_CR20","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1681\/ASN.2018060590","volume":"29","author":"FT Chebib","year":"2018","unstructured":"Chebib FT, Perrone RD, Chapman AB et al (2018) A practical guide for treatment of rapidly progressive ADPKD with Tolvaptan. J Am Soc Nephrol 29(10):2458\u20132470","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"1062_CR21","doi-asserted-by":"publisher","first-page":"10996","DOI":"10.1038\/s41598-019-47206-4","volume":"9","author":"B Shi","year":"2019","unstructured":"Shi B, Akbari P, Pourafkari M et al (2019) Prognostic performance of kidney volume measurement for polycystic kidney disease: a comparative study of ellipsoid vs manual segmentation. Sci Rep 9(1):10996","journal-title":"Sci Rep"},{"issue":"12","key":"1062_CR22","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.3390\/diagnostics10121113","volume":"10","author":"DD Onthoni","year":"2020","unstructured":"Onthoni DD, Sheng TW, Sahoo PK et al (2020) Deep learning assisted localization of polycystic kidney on contrast-enhanced CT images. Diagnostics (Basel) 10(12):1113","journal-title":"Diagnostics (Basel)"},{"issue":"9903","key":"1062_CR23","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0140-6736(13)61407-5","volume":"382","author":"A Caroli","year":"2013","unstructured":"Caroli A, Perico N, Perna A et al (2013) Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. Lancet 382(9903):1485\u20131495","journal-title":"Lancet"},{"issue":"4","key":"1062_CR24","doi-asserted-by":"publisher","first-page":"e1002777","DOI":"10.1371\/journal.pmed.1002777","volume":"16","author":"N Perico","year":"2019","unstructured":"Perico N, Ruggenenti P, Perna A et al (2019) Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): a randomized, double-blind, placebo-controlled, multicenter trial. PLoS Med 16(4):e1002777","journal-title":"PLoS Med"},{"issue":"7","key":"1062_CR25","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.cgh.2015.12.049","volume":"14","author":"A Pisani","year":"2016","unstructured":"Pisani A, Sabbatini M, Imbriaco M et al (2016) Long-term effects of octreotide on liver volume in patients with polycystic kidney and liver disease. Clin Gastroenterol Hepatol 14(7):1022-1030.e4","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"275","key":"1062_CR26","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.ijcard.2018.10.063","volume":"15","author":"L Spinelli","year":"2019","unstructured":"Spinelli L, Pisani A, Giugliano G et al (2019) Left ventricular dysfunction in ADPKD and effects of octreotide-LAR: a cross-sectional and longitudinal substudy of the ALADIN trial. Int J Cardiol 15(275):145\u2013151","journal-title":"Int J Cardiol"},{"issue":"19","key":"1062_CR27","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1001\/jama.2018.15870","volume":"320","author":"E Meijer","year":"2018","unstructured":"Meijer E, Visser FW, van Aerts RMM et al (2018) Effect of lanreotide on kidney function in patients with autosomal dominant polycystic kidney disease: the DIPAK 1 randomized clinical trial. JAMA 320(19):2010\u20132019","journal-title":"JAMA"},{"issue":"3","key":"1062_CR28","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1681\/ASN.2015010016","volume":"27","author":"E Cornec-Le Gall","year":"2016","unstructured":"Cornec-Le Gall E, Audr\u00e9zet MP, Rousseau A et al (2016) The PROPKD Score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 27(3):942\u2013951","journal-title":"J Am Soc Nephrol"},{"issue":"24","key":"1062_CR29","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","volume":"371","author":"RW Schrier","year":"2014","unstructured":"Schrier RW, Abebe KZ, Perrone RD et al (2014) Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med 371(24):2255\u20132266","journal-title":"N Engl J Med"},{"issue":"11","key":"1062_CR30","first-page":"1857","volume":"32","author":"MV Irazabal","year":"2017","unstructured":"Irazabal MV, Abebe KZ, Bae KT et al (2017) Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial. Nephrol Dial Transplant 32(11):1857\u20131865","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"1062_CR31","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2215\/CJN.04180609","volume":"5","author":"I Barash","year":"2010","unstructured":"Barash I, Ponda MP, Goldfarb DS et al (2010) A pilot clinical study to evaluate changes in urine osmolality and urine cAMP in response to acute and chronic water loading in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 5(4):693\u2013697","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"1062_CR32","doi-asserted-by":"publisher","first-page":"192","DOI":"10.2215\/CJN.03950510","volume":"6","author":"CJ Wang","year":"2011","unstructured":"Wang CJ, Creed C, Winklhofer FT et al (2011) Water prescription in autosomal dominant polycystic kidney disease: a pilot study. Clin J Am Soc Nephrol 6(1):192\u2013197","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"1062_CR33","doi-asserted-by":"crossref","first-page":"e018794","DOI":"10.1136\/bmjopen-2017-018794","volume":"8","author":"ATY Wong","year":"2018","unstructured":"Wong ATY, Mannix C, Grantham JJ et al (2018) Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD). BMJ Open 8(1):e018794","journal-title":"BMJ Open"},{"issue":"2","key":"1062_CR34","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.kint.2016.10.018","volume":"91","author":"VE Torres","year":"2017","unstructured":"Torres VE, Abebe KZ, Schrier RW et al (2017) Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease. Kidney Int 91(2):493\u201350035","journal-title":"Kidney Int"},{"issue":"3","key":"1062_CR35","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s10157-012-0706-3","volume":"17","author":"A Ozkok","year":"2013","unstructured":"Ozkok A, Akpinar TS, Tufan F et al (2013) Clinical characteristics and predictors of progression of chronic kidney disease in autosomal dominant polycystic kidney disease: a single center experience. Clin Exp Nephrol 17(3):345\u2013351","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"1062_CR36","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1210\/jcem-51-1-170","volume":"51","author":"JW Rowe","year":"1980","unstructured":"Rowe JW, Kilgore A, Robertson GL (1980) Evidence in man that cigarette smoking induces vasopressin release via an airway-specific mechanism. J Clin Endocrinol Metab 51(1):170\u2013172","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1062_CR37","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s40620-017-0396-8","volume":"31","author":"L Girardat-Rotar","year":"2018","unstructured":"Girardat-Rotar L, Puhan MA, Braun J et al (2018) Long-term effect of coffee consumption on autosomal dominant polycystic kidneys disease progression: results from the Suisse ADPKD, a Prospective Longitudinal Cohort Study. J Nephrol 31(1):87\u201394","journal-title":"J Nephrol"},{"issue":"7","key":"1062_CR38","doi-asserted-by":"publisher","first-page":"e0181087","DOI":"10.1371\/journal.pone.0181087","volume":"12","author":"X Wang","year":"2017","unstructured":"Wang X, Yamada S, LaRiviere WB et al (2017) Generation and phenotypic characterization of Pde1a mutant mice. PLoS ONE 12(7):e0181087","journal-title":"PLoS ONE"},{"issue":"2","key":"1062_CR39","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11095-019-2726-0","volume":"37","author":"JL Woodhead","year":"2020","unstructured":"Woodhead JL, Pellegrini L, Shoda LKM et al (2020) Comparison of the hepatotoxic potential of two treatments for autosomal-dominant polycystic kidney disease using quantitative systems toxicology modeling. Pharm Res 37(2):24","journal-title":"Pharm Res"},{"issue":"6","key":"1062_CR40","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1159\/000500667","volume":"49","author":"X Wang","year":"2019","unstructured":"Wang X, Constans MM, Chebib FT et al (2019) Effect of a vasopressin V2 receptor antagonist on polycystic kidney disease development in a rat model. Am J Nephrol 49(6):487\u2013493","journal-title":"Am J Nephrol"},{"issue":"4","key":"1062_CR41","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrd4228","volume":"13","author":"DH Maurice","year":"2014","unstructured":"Maurice DH, Ke H, Ahmad F et al (2014) Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov 13(4):290\u2013314","journal-title":"Nat Rev Drug Discov"},{"issue":"27","key":"1062_CR42","doi-asserted-by":"publisher","first-page":"13320","DOI":"10.1073\/pnas.1822113116","volume":"116","author":"F Omar","year":"2019","unstructured":"Omar F, Findlay JE, Carfray G et al (2019) Small-molecule allosteric activators of PDE4 long form cyclic AMP phosphodiesterases. Proc Natl Acad Sci USA 116(27):13320\u201313329","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"1062_CR43","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/sj.bjp.0704743","volume":"136","author":"SJ MacKenzie","year":"2002","unstructured":"MacKenzie SJ, Baillie GS, McPhee I et al (2002) Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 (UCR1). Br J Pharmacol 136(3):421\u2013433","journal-title":"Br J Pharmacol"},{"issue":"6","key":"1062_CR44","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/ki.2008.246","volume":"74","author":"M Albaqumi","year":"2008","unstructured":"Albaqumi M, Srivastava S, Li Z et al (2008) KCa3.1 potassium channels are critical for cAMP-dependent chloride secretion and cyst growth in autosomal-dominant polycystic kidney disease. Kidney Int. 74(6):740\u2013749","journal-title":"Kidney Int."},{"issue":"1","key":"1062_CR45","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1681\/ASN.2006010086","volume":"18","author":"ANT Nguyen","year":"2007","unstructured":"Nguyen ANT, Wallace DP, Blanco G (2007) Ouabain binds with high affinity to the Na, K-ATPase in human polycystic kidney cells and induces extracellular signal-regulated kinase activation and cell proliferation. J Am Soc Nephrol 18(1):46\u201357","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"1062_CR46","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1681\/ASN.2016111232","volume":"28","author":"V Tesar","year":"2017","unstructured":"Tesar V, Ciechanowski K, Pei Y, Barash I et al (2017) Bosutinib versus placebo for autosomal dominant polycystic kidney disease. J Am Soc Nephrol 28(11):3404\u20133413","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"1062_CR47","doi-asserted-by":"publisher","first-page":"C522","DOI":"10.1152\/ajpcell.00163.2010","volume":"301","author":"J Elliott","year":"2011","unstructured":"Elliott J, Zheleznova NN, Wilson PD (2011) c-Src inactivation reduces renal epithelial cell-matrix adhesion, proliferation, and cyst formation. Am J Physiol Cell Physiol 301(2):C522\u2013C529","journal-title":"Am J Physiol Cell Physiol"},{"issue":"4","key":"1062_CR48","doi-asserted-by":"publisher","first-page":"188","DOI":"10.5527\/wjn.v6.i4.188","volume":"6","author":"WE Sweeney","year":"2017","unstructured":"Sweeney WE, Frost P, Avner ED et al (2017) Tesevatinib ameliorates progression of polycystic kidney disease in rodent models of autosomal recessive polycystic kidney disease. World J Nephrol 6(4):188\u2013200","journal-title":"World J Nephrol"},{"issue":"1","key":"1062_CR49","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/ki.2010.355","volume":"79","author":"BY Reed","year":"2011","unstructured":"Reed BY, Masoumi A, Elhassan E et al (2011) Angiogenic growth factors correlate with disease severity in young patients with autosomal dominant polycystic kidney disease. Kidney Int 79(1):128\u2013134","journal-title":"Kidney Int"},{"issue":"11","key":"1062_CR50","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1038\/sj.ki.5002550","volume":"72","author":"Y Tao","year":"2007","unstructured":"Tao Y, Kim J, Yin Y et al (2007) VEGF receptor inhibition slows the progression of polycystic kidney disease. Kidney Int 72(11):1358\u20131366","journal-title":"Kidney Int"},{"issue":"4","key":"1062_CR51","doi-asserted-by":"publisher","first-page":"F773","DOI":"10.1152\/ajprenal.00058.2011","volume":"301","author":"S Raina","year":"2011","unstructured":"Raina S, Honer M, Kr\u00e4mer SD et al (2011) Anti-VEGF antibody treatment accelerates polycystic kidney disease. Am J Physiol Renal Physiol 301(4):F773\u2013F783","journal-title":"Am J Physiol Renal Physiol"},{"issue":"6","key":"1062_CR52","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1073\/pnas.1011498108","volume":"108","author":"V Takiar","year":"2011","unstructured":"Takiar V, Nishio S, Seo-Mayer P et al (2011) Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc Natl Acad Sci USA 108(6):2462\u20132467","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"1062_CR53","doi-asserted-by":"publisher","first-page":"7161","DOI":"10.1038\/s41598-017-07300-x","volume":"7","author":"MY Chang","year":"2017","unstructured":"Chang MY, Ma TL, Hung CC et al (2017) Metformin inhibits cyst formation in a Zebrafish model of polycystin-2 deficiency. Sci Rep 7(1):7161","journal-title":"Sci Rep"},{"issue":"11","key":"1062_CR54","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s10157-019-01770-1","volume":"23","author":"I Capuano","year":"2019","unstructured":"Capuano I, Riccio E, Caccavallo S et al (2019) ADPKD and metformin: from bench to bedside. Clin Exp Nephrol 23(11):1341\u20131342","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"1062_CR55","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12882-018-1090-3","volume":"19","author":"A Pisani","year":"2018","unstructured":"Pisani A, Riccio E, Bruzzese D et al (2018) Metformin in autosomal dominant polycystic kidney disease: experimental hypothesis or clinical fact? BMC Nephrol 19(1):282","journal-title":"BMC Nephrol"},{"issue":"24","key":"1062_CR56","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1161\/CIRCULATIONAHA.106.630194","volume":"114","author":"W Sun","year":"2006","unstructured":"Sun W, Lee TS, Zhu M et al (2006) Statins activate AMP-activated protein kinase in vitro and in vivo. Circulation 114(24):2655\u20132656","journal-title":"Circulation"},{"issue":"1","key":"1062_CR57","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3109\/00365590903359908","volume":"44","author":"RG Fassett","year":"2010","unstructured":"Fassett RG, Coombes JS, Packham D et al (2010) Effect of pravastatin on kidney function and urinary protein excretion in autosomal dominant polycystic kidney disease. Scand J Urol Nephrol 44(1):56\u201361","journal-title":"Scand J Urol Nephrol"},{"issue":"3","key":"1062_CR58","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/0272-6386(95)90497-2","volume":"26","author":"RD Gile","year":"1995","unstructured":"Gile RD, Cowley BD Jr, Gattone VH 2nd et al (1995) Effect of lovastatin on the development of polycystic kidney disease in the Han:SPRD rat. Am J Kidney Dis 26(3):501\u2013507","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"1062_CR59","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1093\/ndt\/16.11.2152","volume":"16","author":"MA van Dijk","year":"2001","unstructured":"van Dijk MA, Kamper AM, van Veen S et al (2001) Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 16(11):2152\u20132157","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"1062_CR60","doi-asserted-by":"publisher","first-page":"889","DOI":"10.2215\/CJN.08350813","volume":"9","author":"MA Cadnapaphornchai","year":"2014","unstructured":"Cadnapaphornchai MA, George DM, McFann K et al (2014) Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 9(5):889\u2013896","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"1062_CR61","first-page":"109","volume":"13","author":"GM Brosnahan","year":"2017","unstructured":"Brosnahan GM, Abebe KZ, Rahbari-Oskoui FF et al (2017) Effect of statin therapy on the progression of autosomal dominant polycystic kidney disease. a secondary analysis of the HALT PKD Trials. Curr Hypertens Rev 13(2):109\u2013120","journal-title":"Curr Hypertens Rev"},{"issue":"1","key":"1062_CR62","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.bbrc.2005.04.095","volume":"332","author":"W Motomura","year":"2005","unstructured":"Motomura W, Tanno S, Takahashi N et al (2005) Involvement of MEK-ERK signalling pathway in the inhibition of cell growth by troglitazone in human pancreatic cancer cells. Biochem Biophys Res Commun 332(1):89\u201394","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"1062_CR63","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/labinvest.2008.104","volume":"89","author":"T Kawai","year":"2009","unstructured":"Kawai T, Masaki T, Doi S et al (2009) PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta. Lab Invest 89(1):47\u201358","journal-title":"Lab Invest"},{"issue":"1","key":"1062_CR64","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1038\/s41598-020-58382-z","volume":"10","author":"AA Kanhai","year":"2020","unstructured":"Kanhai AA, Bange H, Verburg L et al (2020) Renal cyst growth is attenuated by a combination treatment of tolvaptan and pioglitazone, while pioglitazone treatment alone is not effective. Sci Rep 10(1):1672","journal-title":"Sci Rep"},{"issue":"15","key":"1062_CR65","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1093\/hmg\/11.15.1731","volume":"11","author":"S Muto","year":"2002","unstructured":"Muto S, Aiba A, Saito Y et al (2002) Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant. Hum Mol Genet 11(15):1731\u20131742","journal-title":"Hum Mol Genet"},{"issue":"3","key":"1062_CR66","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1515\/jtim-2016-0028","volume":"4","author":"SM Flaig","year":"2016","unstructured":"Flaig SM, Gattone VH, Blazer-Yost BL (2016) Inhibition of cyst growth in PCK and Wpk rat models of polycystic kidney disease with low doses of peroxisome proliferator-activated receptor \u03b3 agonists. J Transl Int Med 4(3):118\u2013126","journal-title":"J Transl Int Med"},{"issue":"1","key":"1062_CR67","doi-asserted-by":"publisher","first-page":"F55","DOI":"10.1152\/ajprenal.00090.2009","volume":"297","author":"C Nofziger","year":"2009","unstructured":"Nofziger C, Brown KK, Smith CD et al (2009) PPARgamma agonists inhibit vasopressin-mediated anion transport in the MDCK-C7 cell line. Am J Physiol Renal Physiol 297(1):F55-62","journal-title":"Am J Physiol Renal Physiol"},{"issue":"4","key":"1062_CR68","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/nm.3092","volume":"19","author":"I Rowe","year":"2013","unstructured":"Rowe I, Chiaravalli M, Mannella V et al (2013) Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy. Nat Med 19(4):488\u2013493","journal-title":"Nat Med"},{"issue":"7","key":"1062_CR69","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1681\/ASN.2015030231","volume":"27","author":"M Chiaravalli","year":"2016","unstructured":"Chiaravalli M, Rowe I, Mannella V et al (2016) 2-Deoxy-d-glucose ameliorates PKD progression. J Am Soc Nephrol 27(7):1958\u20131969","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"1062_CR70","doi-asserted-by":"publisher","first-page":"e0146654","DOI":"10.1371\/journal.pone.0146654","volume":"11","author":"M Riwanto","year":"2016","unstructured":"Riwanto M, Kapoor S, Rodriguez D et al (2016) Inhibition of aerobic glycolysis attenuates disease progression in polycystic kidney disease. PLoS ONE 11(1):e0146654","journal-title":"PLoS ONE"},{"issue":"9","key":"1062_CR71","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1056\/NEJMoa1003491","volume":"363","author":"G Walz","year":"2010","unstructured":"Walz G, Budde K, Mannaa M et al (2010) Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 363(9):830\u2013840","journal-title":"N Engl J Med"},{"issue":"9","key":"1062_CR72","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1056\/NEJMoa0907419","volume":"363","author":"AL Serra","year":"2010","unstructured":"Serra AL, Poster D, Kistler AD et al (2010) Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 363(9):820\u2013829","journal-title":"N Engl J Med"},{"issue":"11","key":"1062_CR73","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s11255-019-02292-1","volume":"51","author":"CH Lin","year":"2019","unstructured":"Lin CH, Chao CT, Wu MY et al (2019) Use of mammalian target of rapamycin inhibitors in patient with autosomal dominant polycystic kidney disease: an updated meta-analysis. Int Urol Nephrol 51(11):2015\u20132025","journal-title":"Int Urol Nephrol"},{"key":"1062_CR74","doi-asserted-by":"publisher","first-page":"100154","DOI":"10.1016\/j.phanu.2019.100154","volume":"9","author":"F Testa","year":"2019","unstructured":"Testa F, Marchi\u00f2 M, Belli M et al (2019) A pilot study to evaluate tolerability and safety of a modified Atkins diet in ADPKD patients. PharmaNutrition 9:100154","journal-title":"PharmaNutrition"},{"issue":"8","key":"1062_CR75","doi-asserted-by":"publisher","first-page":"F726","DOI":"10.1152\/ajprenal.00551.2015","volume":"310","author":"KR Kipp","year":"2016","unstructured":"Kipp KR, Rezaei M, Lin L et al (2016) A mild reduction of food intake slows disease progression in an orthologous mouse model of polycystic kidney disease. Am J Physiol Renal Physiol 310(8):F726\u2013F731","journal-title":"Am J Physiol Renal Physiol"},{"issue":"3","key":"1062_CR76","doi-asserted-by":"publisher","first-page":"F662","DOI":"10.1152\/ajprenal.00421.2009","volume":"298","author":"HJ Kim","year":"2010","unstructured":"Kim HJ, Vaziri ND (2010) Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure. Am J Physiol Renal Physiol 298(3):F662\u2013F671","journal-title":"Am J Physiol Renal Physiol"},{"issue":"4","key":"1062_CR77","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1056\/NEJMoa1105351","volume":"365","author":"PE Pergola","year":"2011","unstructured":"Pergola PE, Raskin P, Toto RD et al (2011) Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 365(4):327\u2013336","journal-title":"N Engl J Med"},{"issue":"26","key":"1062_CR78","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1056\/NEJMoa1306033","volume":"369","author":"D de Zeeuw","year":"2013","unstructured":"de Zeeuw D, Akizawa T, Audhya P et al (2013) Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 369(26):2492\u20132503","journal-title":"N Engl J Med"},{"issue":"554","key":"1062_CR79","doi-asserted-by":"publisher","first-page":"eaba3613","DOI":"10.1126\/scitranslmed.aba3613","volume":"12","author":"Y Lu","year":"2020","unstructured":"Lu Y, Sun Y, Liu Z et al (2020) Activation of NRF2 ameliorates oxidative stress and cystogenesis in autosomal dominant polycystic kidney disease. Sci Transl Med 12(554):eaba3613","journal-title":"Sci Transl Med"},{"key":"1062_CR80","doi-asserted-by":"publisher","first-page":"109526","DOI":"10.1016\/j.cellsig.2020.109526","volume":"69","author":"TA Natoli","year":"2020","unstructured":"Natoli TA, Modur V, Beskrovnaya OI (2020) Glycosphingolipid metabolism and polycystic kidney disease. Cell Signal 69:109526","journal-title":"Cell Signal"},{"issue":"7","key":"1062_CR81","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/nm.2171","volume":"16","author":"TA Natoli","year":"2010","unstructured":"Natoli TA, Smith LA, Rogers KA et al (2010) Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models. Nat Med 16(7):788\u2013792","journal-title":"Nat Med"},{"issue":"1","key":"1062_CR82","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1053\/j.gastro.2010.04.010","volume":"139","author":"SA Gradilone","year":"2010","unstructured":"Gradilone SA, Masyuk TV, Huang BQ et al (2010) Activation of Trpv4 reduces the hyperproliferative phenotype of cystic cholangiocytes from an animal model of ARPKD. Gastroenterology 139(1):304\u201314.e2","journal-title":"Gastroenterology"},{"issue":"6","key":"1062_CR83","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/ki.2011.139","volume":"80","author":"NX Chen","year":"2011","unstructured":"Chen NX, Moe SM, Eggleston-Gulyas T et al (2011) Calcimimetics inhibit renal pathology in rodent nephronophthisis. Kidney Int 80(6):612\u2013619","journal-title":"Kidney Int"},{"issue":"7","key":"1062_CR84","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1681\/ASN.2008090927","volume":"20","author":"VH Gattone 2nd","year":"2009","unstructured":"Gattone VH 2nd, Chen NX, Sinders RM et al (2009) Calcimimetic inhibits late-stage cyst growth in ADPKD. J Am Soc Nephrol 20(7):1527\u20131532","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"1062_CR85","doi-asserted-by":"publisher","first-page":"5704","DOI":"10.1038\/s41598-018-23732-5","volume":"8","author":"A Di Mise","year":"2018","unstructured":"Di Mise A, Tamma G, Ranieri M et al (2018) Activation of calcium-sensing receptor increases intracellular calcium and decreases cAMP and mTOR in PKD1 deficient cells. Sci Rep 8(1):5704","journal-title":"Sci Rep"},{"issue":"12","key":"1062_CR86","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.chembiol.2005.09.009","volume":"12","author":"SJ Leuenroth","year":"2005","unstructured":"Leuenroth SJ, Crews CM (2005) Studies on calcium dependence reveal multiple modes of action for triptolide. Chem Biol 12(12):1259\u20131268","journal-title":"Chem Biol"},{"issue":"11","key":"1062_CR87","doi-asserted-by":"publisher","first-page":"4389","DOI":"10.1073\/pnas.0700499104","volume":"104","author":"SJ Leuenroth","year":"2007","unstructured":"Leuenroth SJ, Okuhara D, Shotwell JD et al (2007) Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease. Proc Natl Acad Sci USA 104(11):4389\u20134394","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"1062_CR88","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1681\/ASN.2008030259","volume":"19","author":"SJ Leuenroth","year":"2008","unstructured":"Leuenroth SJ, Bencivenga N, Igarashi P et al (2008) Triptolide reduces cystogenesis in a model of ADPKD. J Am Soc Nephrol 19(9):1659\u20131662","journal-title":"J Am Soc Nephrol"},{"issue":"21","key":"1062_CR89","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.4161\/cc.22375","volume":"11","author":"NO Bukanov","year":"2012","unstructured":"Bukanov NO, Moreno SE, Natoli TA et al (2012) CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD. Cell Cycle 11(21):4040\u20134046","journal-title":"Cell Cycle"},{"issue":"3","key":"1062_CR90","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1053\/j.gastro.2011.11.036","volume":"142","author":"TV Masyuk","year":"2012","unstructured":"Masyuk TV, Radtke BN, Stroope AJ et al (2012) Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease. Gastroenterology 142(3):622-633.e4","journal-title":"Gastroenterology"},{"issue":"4","key":"1062_CR91","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1046\/j.1523-1755.2000.00991.x","volume":"57","author":"T Yamaguchi","year":"2000","unstructured":"Yamaguchi T, Pelling JC, Ramaswamy NT et al (2000) cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int 57(4):1460\u20131471","journal-title":"Kidney Int"},{"issue":"5","key":"1062_CR92","doi-asserted-by":"publisher","first-page":"F944","DOI":"10.1152\/ajprenal.00387.2010","volume":"299","author":"T Yamaguchi","year":"2010","unstructured":"Yamaguchi T, Reif GA, Calvet JP et al (2010) Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells. Am J Physiol Renal Physiol 299(5):F944\u2013F951","journal-title":"Am J Physiol Renal Physiol"},{"issue":"11","key":"1062_CR93","doi-asserted-by":"publisher","first-page":"3458","DOI":"10.1093\/ndt\/gfr432","volume":"26","author":"B Buchholz","year":"2011","unstructured":"Buchholz B, Klanke B, Schley G et al (2011) The Raf kinase inhibitor PLX5568 slows cyst proliferation in rat polycystic kidney disease but promotes renal and hepatic fibrosis. Nephrol Dial Transplant 26(11):3458\u20133465","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"1062_CR94","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1681\/ASN.2006040353","volume":"17","author":"JP Calvet","year":"2006","unstructured":"Calvet JP (2006) MEK inhibition holds promise for polycystic kidney disease. J Am Soc Nephrol 17(6):1498\u20131500","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"1062_CR95","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1267\/ahc.08040","volume":"42","author":"Y Okumura","year":"2009","unstructured":"Okumura Y, Sugiyama N, Tanimura S et al (2009) ERK regulates renal cell proliferation and renal cyst expansion in inv mutant mice. Acta Histochem Cytochem 42(2):39\u201345","journal-title":"Acta Histochem Cytochem"},{"issue":"1","key":"1062_CR96","doi-asserted-by":"publisher","first-page":"5584","DOI":"10.1038\/s41598-018-22938-x","volume":"8","author":"Y Liu","year":"2018","unstructured":"Liu Y, Pejchinovski M, Wang X et al (2018) Dual mTOR\/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease. Sci Rep 8(1):5584","journal-title":"Sci Rep"},{"issue":"51","key":"1062_CR97","doi-asserted-by":"publisher","first-page":"21819","DOI":"10.1073\/pnas.0911987106","volume":"106","author":"Y Cao","year":"2009","unstructured":"Cao Y, Semanchik N, Lee SH et al (2009) Chemical modifier screen identifies HDAC inhibitors as suppressors of PKD models. Proc Natl Acad Sci USA 106(51):21819\u201321824","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"1062_CR98","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/ki.2011.296","volume":"81","author":"LX Fan","year":"2012","unstructured":"Fan LX, Li X, Magenheimer B et al (2012) Inhibition of histone deacetylases targets the transcription regulator Id2 to attenuate cystic epithelial cell proliferation. Kidney Int 81(1):76\u201385","journal-title":"Kidney Int"},{"issue":"1","key":"1062_CR99","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.kint.2016.01.026","volume":"90","author":"L Cebotaru","year":"2016","unstructured":"Cebotaru L, Liu Q, Yanda MK et al (2016) Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease. Kidney Int 90(1):90\u201399","journal-title":"Kidney Int"},{"issue":"4","key":"1062_CR100","doi-asserted-by":"publisher","first-page":"F997","DOI":"10.1152\/ajprenal.00186.2017","volume":"313","author":"MK Yanda","year":"2017","unstructured":"Yanda MK, Liu Q, Cebotaru L et al (2017) An inhibitor of histone deacetylase 6 activity, ACY-1215, reduces cAMP and cyst growth in polycystic kidney disease. Am J Physiol Renal Physiol 313(4):F997\u2013F1004","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"1062_CR101","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1159\/000369149","volume":"129","author":"C Zoja","year":"2015","unstructured":"Zoja C, Corna D, Locatelli M et al (2015) Effects of MCP-1 inhibition by bindarit therapy in a rat model of polycystic kidney disease. Nephron 129(1):52\u201361","journal-title":"Nephron"},{"issue":"8","key":"1062_CR102","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/nm1783","volume":"14","author":"X Li","year":"2008","unstructured":"Li X, Magenheimer BS, Xia S et al (2008) A tumor necrosis factor-alpha-mediated pathway promoting autosomal dominant polycystic kidney disease. Nat Med 14(8):863\u2013868","journal-title":"Nat Med"},{"issue":"7","key":"1062_CR103","doi-asserted-by":"publisher","first-page":"7743","DOI":"10.1007\/s11033-012-1611-2","volume":"39","author":"T Xu","year":"2012","unstructured":"Xu T, Wang NS, Fu LL et al (2012) Celecoxib inhibits growth of human autosomal dominant polycystic kidney cyst-lining epithelial cells through the VEGF\/Raf\/MAPK\/ERK signaling pathway. Mol Biol Rep 39(7):7743\u20137753","journal-title":"Mol Biol Rep"},{"issue":"9","key":"1062_CR104","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.3727\/096368914X684619","volume":"24","author":"F Franchi","year":"2015","unstructured":"Franchi F, Peterson KM, Xu R et al (2015) Mesenchymal stromal cells improve renovascular function in polycystic kidney disease. Cell Transplant 24(9):1687\u20131698","journal-title":"Cell Transplant"},{"key":"1062_CR105","doi-asserted-by":"publisher","first-page":"100206","DOI":"10.1016\/j.phanu.2020.100206","volume":"13","author":"F Testa","year":"2020","unstructured":"Testa F, Marchi\u00f2 M, D\u2019Amico R (2020) GREASE II. A phase II randomized, 12-month, parallel-group, superiority study to evaluate the efficacy of a modified Atkins diet in autosomal dominant polycystic kidney disease patients. PharmaNutrition 13:100206","journal-title":"PharmaNutrition"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-021-01062-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-021-01062-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-021-01062-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:55:59Z","timestamp":1777564559000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/35\/2\/397\/8326112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,19]]},"references-count":105,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1062"],"URL":"https:\/\/doi.org\/10.1007\/s40620-021-01062-6","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,19]]},"assertion":[{"value":"13 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare that are relevant to the contents of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this type of study (i.e. review article) ethical approval is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}]}}